Guidance for Industry: Recommendations for Donor Questioning, Deferral, Reentry and Product Management to Reduce the Risk of Transfusion-Transmitted Malaria
WHO has urged Indonesia, one of the world's biggest advocates of two malaria drugs to treat the coronavirus, to suspend such treatment over safety concerns, a source familiar with the advice told Reuters on Tuesday.Reuters Health Information
In this study, the anti-inflammatory and immunomodulatory activities of the methanol-dichloromethane extract (MDE) from the stem bark of the plant in rodents were evaluated. Methods: The carrageenan-induced rat paw oedema, cotton pellet-induced granuloma in rat, and xylene-induced ear oedema in mice were used to study the anti-inflammatory activity of methanol-dichloromethane extract of Stemonocoleus micranthus (MDESm) (100, 200, and 400 mg/kg). The effects of MDESm (100, 200, and 400 mg/kg) on cyclophosphamide-induced immunosuppression, neutrophil adhesion, carbon clearance, and haematological and bioche...
France, Italy and Belgium acted to halt the use of hydroxychloroquine to treat patients suffering from COVID-19, the illness caused by the new coronavirus, amid questions about the safety of the generic anti-malaria drug.
FDA has approved artesunate for injection to treat severe malaria in adult and pediatric patients.
The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine, probably by mid-June, after safety concerns prompted the group to suspend the malaria drug's use in a large trial on COVID-19 patients.
The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to potential safety risks but other studies testing the medicine are continuing.
The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.Reuters Health Information
The World Health Organization (WHO) has temporarily suspended the malaria drug hydroxychloroquine from a global trial for COVID-19 treatments for a safety review. Dr. David Agus joins "CBS This Morning" to explain why the drug was dropped from the global study. He also addresses the WHO warning that countries reopening could face an "immediate second peak" of the virus if safety measures are lifted too soon.
Publication date: Available online 26 May 2020Source: Parasitology InternationalAuthor(s): Ralph E.T. Vanstreels, Daniela de Angeli Dutra, Allan P. Santos, Renata Hurtado, Leandro Egert, Érika M. Braga
(Reuters)—Malaria drug hydroxychloroquine (HCQ), which U.S. President Donald Trump says he has been taking, is tied to increased risk of death in COVID-19 patients, according to a study published in The Lancet.1 The registry analysis, which included data from 671 hospitals in six continents and over 96,000 patients hospitalized with COVID-19, showed that people treated... [Read More]